Free Trial
NASDAQ:FEMY

Femasys 8/8/2024 Earnings Report

Femasys logo
$0.36 +0.01 (+1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$0.36 +0.00 (+0.61%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$280.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Femasys Earnings Headlines

Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.tc pixel
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools.

Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.

View Femasys Profile